Irbesartan Tarbis

Irbesartan, the active ingredient in Irbesartan Tarbis, is an angiotensin II receptor blocker presented as an oral dosage form for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetes, as well as to aid heart failure management in adults.

GNH USA supplies Irbesartan Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Irbesartan is an angiotensin II receptor blocker used to treat conditions related to the renin‑angiotensin system.

- Hypertension: provides sustained blood pressure reduction, helping to lower the risk of stroke, myocardial infarction and other cardiovascular events. - Diabetic nephropathy: slows the decline of renal function and reduces albuminuria in patients with type 2 diabetes and established kidney disease. - Heart failure: improves left ventricular function and decreases symptoms such as dyspnea, contributing to reduced hospital admissions in systolic heart failure.

Irbesartan may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: feeling of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness. - Upper respiratory tract infection: nasopharyngitis symptoms.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium that can cause cardiac arrhythmias. - Angioedema: swelling of face, lips, tongue or airway requiring emergency care. - Renal impairment: sudden decrease in kidney function, especially in patients with pre‑existing renal disease.

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure patient safety. - Renal function monitoring: assess serum creatinine and eGFR before initiation and periodically during therapy. - Electrolyte assessment: check serum potassium levels, particularly in patients receiving potassium‑sparing diuretics or supplements. - Concomitant ACE inhibitor or ARB therapy: avoid combined use due to increased risk of renal dysfunction and hyperkalemia. - Pregnancy: discontinue if pregnancy is confirmed, as safety data are limited. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with ACE inhibitors or other ARBs: may cause additive renal impairment and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone) or potassium supplements: increase risk of hyperkalemia. - Strong CYP2C9 inhibitors (e.g., fluconazole): raise Irbesartan plasma concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may reduce antihypertensive effect and affect renal function. - Diuretics (e.g., thiazides): may enhance hypotensive response. - Lithium: may increase lithium levels, requiring serum monitoring.